Copyright
©The Author(s) 2023.
World J Gastrointest Surg. Dec 27, 2023; 15(12): 2727-2738
Published online Dec 27, 2023. doi: 10.4240/wjgs.v15.i12.2727
Published online Dec 27, 2023. doi: 10.4240/wjgs.v15.i12.2727
Figure 3 Hepatocellular carcinoma recurrence and its association with tacrolimus trough concentration.
A: Survival curve presenting difference in the graft survival between hepatocellular carcinoma (HCC) recurrence (n = 13) and non-recurrence (n = 34); B: Comparison of tacrolimus concentrations in the HCC recurrence (n = 13) and non-recurrence (n = 34) groups at each time point (left) and at 4 wk (right); C and D: Two patients who died during the perioperative period from postoperative complication or sepsis were excluded; C: Survival curves presenting recurrence-free survival (RFS) according to tacrolimus trough concentration at 4 wk post-liver transplantation (LT) before propensity-score matching (> 7.3 ng/mL, n = 13 vs ≤ 7.3 ng/mL, n = 34) and after matching (> 7.3 ng/mL, n = 12 vs ≤ 7.3 ng/mL, n = 12); Patients for whom tacrolimus concentrations 4 wk post-LT were not reported were excluded from the analyses; D: Prior to transplantation, patients were assigned to subgroups according to the Milan criteria in the pre-LT radiologic evaluation. RFS curves for each subgroup according to trough tacrolimus concentration at 4 wk post-LT are presented. ABOi: ABO-incompatible; FK: Tacrolimus; HCC: Hepatocellular carcinoma; LT: Liver transplantation. aP < 0.05.
- Citation: Han JW, Choi JY, Jung ES, Kim JH, Cho HS, Yoo JS, Sung PS, Jang JW, Yoon SK, Choi HJ, You YK. Association between the early high level of serum tacrolimus and recurrence of hepatocellular carcinoma in ABO-incompatible liver transplantation. World J Gastrointest Surg 2023; 15(12): 2727-2738
- URL: https://www.wjgnet.com/1948-9366/full/v15/i12/2727.htm
- DOI: https://dx.doi.org/10.4240/wjgs.v15.i12.2727